Glenmark Pharmaceuticals: FabiFlu (Favipiravir)

Main article: Drugs for coronavirus COVID-19

2022: Start of supply of the drug from the coronavirus "Favipiravir"

The pharmaceutical company Binnopharm Group on February 2, 2022 announced that it had delivered to the Russian market the first batch of the drug Favipiravir, which was recommended by the Ministry of Health in protocols for the treatment of COVID-19. The registration certificate for the drug was received in September 2021.

The incidence rate of COVID-19 as of February 2022 is at its peak. We did everything to ensure the delivery of the drug necessary to combat the pandemic as quickly as possible. For us, it is produced under a contract in India, at the same time we are working on the possibility of localizing its production at a plant in the village of Obolensk, Moscow Region, "said Rustem Muratov, CEO of Binnofarm Group.

According to Alpha, in the second half of 2021, sales of Favipiravir in kind increased by 5 times (compared to the first half of the year), sales for the year exceeded 8 million packages.

According to temporary methodical recommendations "Prevention, diagnostics and treatment of new coronavirus infection (COVID-19)", version 14 of 28.12.2021 of the Russian Ministry of Health, favipiravir is included into the protocol of treatment of patients with new coronavirus infection.

2021: Localization of production at Binnopharm Group sites

On January 18, 2021 pharmaceutical , the holding "" Binnopharm Group announced that together with the company Glenmark Pharmaceuticals Limited (Glenmark) they agreed to localize the production of the antiviral drug "Favipiravir," intended for treatment at the COVID-19 sites "Binnopharm Group" - the plant "" in Alium the village of Obolensk Moscow region and "" in. Biolump Stavropol Documents for obtaining a registration certificate filed Ministry of Health of the Russian Federation at the end of 2020.

Despite the beginning of mass vaccination, the need for drugs for the treatment of COVID-19 remains high. We, like other Russian manufacturers, are making every effort to provide the country with the necessary medicines, "says Rustem Muratov, general director of Binnopharm Group. - Favipiravir preparations received the approval of the Ministry of Health and the need for it is high, therefore, after completing the necessary procedures, we will promptly begin the supply of this drug produced for us under contract at the Glenmark plant in India, which is certified according to Russian GMP standards, and also localize the production of Favipavir at our sites.

Glenmark Pharmaceuticals Limited will become the supplier of the substance for the production of Favipiravir at Binnopharm Group sites.

Pharmaceutical manufacturers around the world share experiences and help each other develop and produce drugs to combat the spread of coronavirus infection. The Russian market is strategically important for Glenmark and we are glad that Binnopharm Group holding has become our partner in Russia, "said Chaba Kantor, Senior Vice President of Glenmark Pharmaceuticals - Russia and the CIS.

2020: Release of the drug Favipiravir under the brand name FabiFlu

On June 21, 2020, Glenmark Pharmaceuticals announced the release of the antiviral drug Favipiravir under the brand name FabiFlu for the treatment of patients with mild to moderate severity COVID-19 at a price of about Rs 103 per tablet (200 mg).

The Mumbai-based company has received production and marketing approval from the Comptroller General of Medicines of India (DCGI). Favipiravir demonstrated clinical improvement to 88% in mild to moderate cases of COVID-19. The company's statement also said that FabiFlu (Favipiravir) is India's first oral drug approved for the treatment of COVID-19.

According to Glenmark representatives, the drug will be available in the form of a 200 mg tablet at a maximum retail price of Rs. 3,500 per strip of 34 tablets. This is a prescription medicine with a recommended dose of 1800 mg twice a day on the first day, then 800 mg twice a day - until the 14th day. The pills are produced by the company at the Buddy plant in Himachal Pradesh, the drug will be available both in hospitals and through the retail channel^[1].

Notes